Business
CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World
MONMOUTH JUNCTION, N.J., April 14, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J., April 14, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has registered a new subsidiary, CytoSorbents Medical UK Limited, with plans to establish a direct sales presence within the United Kingdom (UK) and Ireland. CytoSorbents previously sold CytoSorb® via distributor partners within the region. With a new direct commercialization presence, CytoSorbents expects to focus its resources and expertise to expand the use of CytoSorb® in hospitals throughout this territory, while providing world-class support and education for physicians and healthcare professionals. The UK is the third largest medical device market in Europe and the sixth largest in the world. CytoSorbents will now directly commercialize its products in 15 countries, with sales in more than 70 countries worldwide.\n\n \n \n \n \n \n \n\n \nCytoSorbents recently hired Mr. Shaun Whittemore as Country Manager - UK & Ireland, to drive and coordinate market development in the region. Mr. Whittemore brings 20 years of sales, marketing and product specialist experience supporting large, global medical technology companies including LivaNova, Johnson & Johnson, and Smith+Nephew. Prior to joining CytoSorbents, Mr. Whittemore was most recently Commercial Manager, UK & Ireland at LivaNova.\n\"I am delighted to be part of this exciting opportunity to further develop and grow the market for CytoSorb in the United Kingdom and the Republic of Ireland and expect to leverage my insight and expertise from a career extending over two decades within the healthcare sector. I believe the benefits of our innovative blood purification technology will make a positive impact on the lives of treated patients throughout the region,\" said Whittemore.\nDr. Christian Steiner, Executive Vice President, Sales and Marketing of CytoSorbents stated, \"As we establish a direct sales team in the UK and Ireland, we are excited to work more closely with physicians to improve awareness and usage of CytoSorb in its many applications in critical care and cardiac surgery. We also expect to continue working with the UK's National Health Service (NHS), one of the world's largest and well-renowned healthcare systems, to educate...